Graham Griffiths
Corporate Officer/Principal bei BARINTHUS BIOTHERAPEUTICS PLC
Vermögen: 253 124 $ am 30.04.2024
Profil
Graham Griffiths was the founder of Agalimmune Ltd.
which was founded in 2013, where he held the title of Chief Operating Officer & Director until 2017.
Currently, he is the Chief Business Officer at Barinthus Biotherapeutics Plc since 2017.
Mr. Griffiths has previously worked as a Director at MET Parking Services Ltd.
from 2005 to 2007.
He also worked as a Fund Manager at Matrix Securities Ltd.
Mr. Griffiths is a graduate of Newcastle University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.03.2024 | 104 209 ( 0,31% ) | 253 124 $ | 30.04.2024 |
Aktive Positionen von Graham Griffiths
| Unternehmen | Position | Beginn |
|---|---|---|
| BARINTHUS BIOTHERAPEUTICS PLC | Corporate Officer/Principal | 01.10.2017 |
Ehemalige bekannte Positionen von Graham Griffiths
| Unternehmen | Position | Ende |
|---|---|---|
Agalimmune Ltd.
 Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Part of BioLineRx Ltd., Agalimmune Ltd. is a British company that develops anti-cancer immunotherapy technology. The company is based in London, UK. The company was founded by Charles Campbell Roberts and Graham Griffiths. The CEO is Mike Westby. Agalimmune was acquired by BioLineRx Ltd. on March 23, 2017 for $6.05 million. | Gründer | 01.09.2017 |
| MET Parking Services Ltd. | Direktor/Vorstandsmitglied | 01.07.2007 |
Matrix Securities Ltd.
 Matrix Securities Ltd. Investment ManagersFinance Matrix Securities Ltd. (MS) is the investment management and services division and a subsidiary of Matrix Group Ltd. Several specialized subsidiaries operate jointly under the Matrix Securities brand. These entities service venture capital trusts, raise capital for private equity funds managed externally, source limited partner interests, administer securitized property and design structured products as well as innovative financing vehicles for film production purposes. MS is also involved in alternative investing through their subsidiary Matrix Alternative Asset Management which manages hedge funds. MS was established in 1987 and is located in London. The firm's clients are European institutions. MS has specialist expertise in raising capital for small entrepreneurial companies. | Corporate Officer/Principal | - |
Ausbildung von Graham Griffiths
| Newcastle University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BARINTHUS BIOTHERAPEUTICS PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Agalimmune Ltd.
Agalimmune Ltd. Pharmaceuticals: MajorHealth Technology Part of BioLineRx Ltd., Agalimmune Ltd. is a British company that develops anti-cancer immunotherapy technology. The company is based in London, UK. The company was founded by Charles Campbell Roberts and Graham Griffiths. The CEO is Mike Westby. Agalimmune was acquired by BioLineRx Ltd. on March 23, 2017 for $6.05 million. | Health Technology |
| MET Parking Services Ltd. | |
Matrix Securities Ltd.
Matrix Securities Ltd. Investment ManagersFinance Matrix Securities Ltd. (MS) is the investment management and services division and a subsidiary of Matrix Group Ltd. Several specialized subsidiaries operate jointly under the Matrix Securities brand. These entities service venture capital trusts, raise capital for private equity funds managed externally, source limited partner interests, administer securitized property and design structured products as well as innovative financing vehicles for film production purposes. MS is also involved in alternative investing through their subsidiary Matrix Alternative Asset Management which manages hedge funds. MS was established in 1987 and is located in London. The firm's clients are European institutions. MS has specialist expertise in raising capital for small entrepreneurial companies. | Finance |
